The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COTI-2 was reported to restore DNA-binding properties to the p53-mutant protein,449,451–453”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [451]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
Research works printed but not linked: 28
- Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van’t Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA et al (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929–1044 · DOI · Paper page
- Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339 · DOI · Paper page
- Stephens PJ, Tarpey PS, Davies H, Van-Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A, Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van’t Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Børresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR, Oslo Breast Cancer Consortium (OSBREAC) (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400–404 · DOI · Paper page
- Network Cancer Genome Atlas (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70 · DOI · Paper page
- Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2:16036 · DOI · Paper page
- Duffy MJ, Synnott NC, Crown J (2017) Mutant p53 as a target for cancer treatment. Eur J Cancer 83:258–265 · DOI · Paper page
- Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH (2017) Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci 74:4171–4187 · DOI
- Salim KY, Maleki Vareki S, Danter WR, Koropatnick J (2016) COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7:41363–41379 · DOI · Paper page
- Maleki Vareki S, Salim KY, Danter WR, Koropatnick J (2018) Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS ONE 13:e0191766 · DOI
- Salim K, Maleki Vareki S, Danter W, Koropatnick J (2016) COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3 K/AKT/mTOR pathway. Eur J Cancer 69:S19 · DOI
- Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA (2019) COTI-2, A novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-19-0096 · DOI · Paper page
- Ho RT, Salim KY, Lindemann A, Patel AM, Takahashi H, Wang L, Zhao M, Frank SJ, Myers J, Osman A, Lynam C, Silva AD (2018) COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models. J Clin Oncol 36:6040 · doi:10.1200/jco.2018.36.15_suppl.6040
- Westin SN, Nieves-Neira W, Lynam C, Salim KY, Silva AD, Ho R, Mills GB, Coleman RL, Janku F, Matei D (2018) Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer. In: Proceedings of the American Association for Cancer Research. http://www.abstractsonline.com/pp8/#!/4562/presentation/11184 · doi:10.1158/1538-7445.am2018-ct033
- Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9:176–198 · DOI · Paper page
- Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O’Donovan N et al (2017) Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer 140(1):234–246 · DOI
- Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O’Donovan N et al (2018) Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett 414:99–106 · DOI
- Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR (2005) Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 280:16030–16037 · DOI · Paper page
- Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A (2018) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 25:104–113 · DOI · Paper page
- Green JA, Von Euler M, Abrahmsen LB (2018) Restoration of conformation of mutant p53. Ann Oncol 29:1325–1328 · DOI · Paper page
- Bauer MR, Joerger AC, Fersht AR (2016) 2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci USA 113(36):E5271–E5280 · DOI
- Gogna R, Madan E, Kuppusamy P, Pati U (2012) Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications. Cell Death Dis 3:e286 · DOI
- Milner J, Watson JV (1990) Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene 5:1683–1690
- Rich RL, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, Hensley P, Myszka DG (2002) Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci USA 99:8562–8567 · doi:10.1073/pnas.142288199
- Fabian C, Tilzer L, Sternson L (1981) Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 2:381–390 · DOI
- Wang S, Konorev E, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem 279:25535–25543 · DOI · Paper page
- Kumar A, Palakurthi S (2013) P53 Gene therapy sensitizes resistant breast cancer cells to doxorubicin chemotherapy. Drug Deliv Lett 3:165–174 · doi:10.2174/2210303111303030002
- Anelli A (2003) Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 14:428–432 · doi:10.1093/annonc/mdg104
- Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 22(321):288–300 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Self-citationGain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Metadata
- Authors
- Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2019-09-19
- Volume
- 179
- Issue
- 1
- Pages
- 47-56
- ISSN
- 0167-6806
- 1573-7217
- Cited by
- 77
- References
- 10
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- Irish Cancer Society (CCRC13GAL)
- Cancer Clinical Research Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. https://app.cochat.ai/papers/10.1007/s10549-019-05435-1
- The paper
- Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J. (2020). COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-019-05435-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.